Associate professor Samantha Barton, who leads the Myelin in Health and Disease Group at The Florey, said the model took more than six years to engineer and marks a significant step forward for the field.

"In science, we typically use rodents to model diseases for research, but drugs identified to work in these models of disease are rarely effective in people, so creating more human-relevant model systems is important," Barton said.

"The relevance of our new system is significant. In addition to generating myelin, we have been able to introduce immune cells to trigger injury similar to MS. This gives us the unique opportunity to study the regenerative process of remyelination in the laboratory," she explained. "This model can help researchers better understand what drives myelin damage and repair in MS and it also gives us a new platform to screen drugs that protect or restore myelin."

Barton added: "The dream is to find new ways to slow or prevent MS progression — we hope our models could help us do that."

A platform for testing drugs

Dr. Shwathy Ramesan, the study's first author and a postdoctoral fellow at The Florey, said the model lets researchers watch candidate drugs acting on human cells in near real time — a capability rodent studies cannot match.

"We are extremely happy with our findings and believe we are closer than ever to creating the best possible platform for MS drug development with the aim of reversing the disease and giving quality health back to people living with MS," Ramesan said. "After years of developing and refining this model, it's exciting to see it provide a window into human myelin biology that wasn't previously available. We hope it becomes a valuable tool not only for our team but for researchers studying MS around the world."

Co-senior author associate professor David Gonsalvez of Monash University highlighted another advantage: the system allows researchers to test therapeutics that could strengthen the body's own, limited capacity for self-repair in the central nervous system.

"We are excited at the prospect of using our new system to identify therapeutics that can actually boost the limited ability we humans all possess to repair our electrical insulation in the central nervous system," Gonsalvez said.

The project brought together experts from The Florey, the University of Melbourne, the University of Auckland, Monash University, WEHI and the University of Canberra.

Caveats and next steps

The findings are promising but early. The organoids are laboratory models, not living brains, and the researchers have so far demonstrated that the system works — actual drug discoveries and any clinical benefit remain ahead. Whether compounds identified through this platform will translate into effective treatments for people with MS will require years of further testing.

Still, the team sees the model as a shared resource. By making human myelin biology visible in the lab for the first time in this way, they hope to give MS researchers worldwide a faster, more faithful route from laboratory bench to bedside.